{"organizations": [], "uuid": "316958e49e697816adc61eb52ec1bd2c86f877a7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-incyte-reports-q1-loss-of-019-per/brief-incyte-reports-q1-loss-of-0-19-per-share-idUSASC09YIO", "country": "US", "domain_rank": 408, "title": "BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.207, "site_type": "news", "published": "2018-05-01T19:27:00.000+03:00", "replies_count": 0, "uuid": "316958e49e697816adc61eb52ec1bd2c86f877a7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-incyte-reports-q1-loss-of-019-per/brief-incyte-reports-q1-loss-of-0-19-per-share-idUSASC09YIO", "ord_in_thread": 0, "title": "BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "incyte corp", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "incyte", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Incyte Corp:\n* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS\n* Q1 NON-GAAP LOSS PER SHARE $0.01\n* Q1 REVENUE $382 MILLION VERSUS I/B/E/S VIEW $389.7 MILLION\n* Q1 LOSS PER SHARE $0.19 * Q1 EARNINGS PER SHARE VIEW $0.01 — THOMSON REUTERS I/B/E/S\n* INTENDS TO CONTINUE TO INVESTIGATE EPACADOSTAT’S POTENTIAL AS A COMPONENT OF COMBINATION IMMUNOTHERAPY IN PROOF-OF-CONCEPT TRIALS\n* TWO TRIALS OF EPACADOSTAT IN COMBINATION WITH PEMBROLIZUMAB IN LUNG CANCER WILL BE CONVERTED INTO RANDOMIZED PHASE 2 TRIALS\n* SEES FY 2018 GAAP AND NON-GAAP JAKAFI NET PRODUCT REVENUES OF $1,350 MILLION - $1,400 MILLION\n* SEES FY 2018 GAAP AND NON-GAAP ICLUSIG NET PRODUCT REVENUES OF $80 MILLION - $85 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T19:27:00.000+03:00", "crawled": "2018-05-02T15:57:02.001+03:00", "highlightTitle": ""}